Karbon opens practice marketplace to all accounting firms
The platform, which launched in September 2024 for the company's customers, is designed to facilitate firm acquisitions through a digital-first approach.
Besides, Karbon introduced the Partners Marketplace, which links firms with mergers and acquisitions (M&A) advisors, Karbon-certified implementers, business coaches, and other professionals to offer guidance through the transition process.
Karbon CEO Mary Delaney said: 'A successful merger relies on alignment of culture, team, tech stack, and processes. And with Practice Marketplace by Karbon, it's now easier for firm owners to be part of the same life-changing process.
'Karbon exists to empower accounting firms to thrive. This initiative is another way we are supporting firms in their journey and enabling them to thrive—whatever that is to them.'
Now, firms looking to sell can list on the Practice Marketplace for a fee, while buyers are required to be fully implemented on Karbon.
This structure is intended to improve efficiency and facilitate smoother acquisitions by integrating the company's tools and processes.
Firms from the US, Canada, Australia, New Zealand, UK and South Africa are currently using the platform.
As industry consolidation ramps up and private equity interest increases, the expanded Practice Marketplace aims to offer firms a structured approach to succession planning and (M&A) opportunities.
Karbon Practice Marketplace program lead Joe Carufe said: 'Practice Marketplace by Karbon provides selling firms with exposure to the best firms globally for a successful exit, while also giving our Karbon-enabled buyers a new and highly qualified source of acquisition opportunities.
'Beyond just connecting buyers and sellers, we're helping firms work with industry-leading M&A experts and business coaches to navigate today's rapidly changing market, ensuring they thrive through succession and strategic growth.'
"Karbon opens practice marketplace to all accounting firms" was originally created and published by International Accounting Bulletin, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
AAHI Partners with Quratis to Strengthen Global Vaccine Manufacturing and Accelerate Access to Lifesaving Vaccines
SEATTLE--(BUSINESS WIRE)--Access to Advanced Health Institute (AAHI), a global leader in translating high-impact science into scalable, field-ready vaccine solutions, today announced an exciting new partnership with Quratis, a premier biotechnology company and advanced Contract Development and Manufacturing Organization (CDMO). This collaboration marks a pivotal step forward in breaking through barriers in global health equity around the world. Under this strategic alliance, Quratis has been selected as AAHI's preferred manufacturer for high-quality pre-clinical and clinical vaccine supplies, with the capacity to expand into commercial-scale production for global markets. This collaboration will accelerate the development of AAHI's innovative vaccine candidates targeting deadly diseases such as tuberculosis, and of vaccines that rely on AAHI's vaccine adjuvants to provide protection against malaria, HIV, and other global health threats. Quratis brings a world-class GMP-certified bioplant and cutting-edge CDMO expertise in biopharmaceutical raw material development, process optimization, and finished pharmaceutical manufacturing. By designating Quratis as preferred partner, AAHI strengthens both its scientific capabilities and access to scalable, cost-effective production of its groundbreaking vaccine formulations—including dry vaccines that eliminate cold chain dependencies and needle-free delivery systems for superior respiratory protection. The partnership ensures a seamless supply chain platform, enabling swift clinical development and broader deployment to the world's most vulnerable populations. "Partnering with Quratis is a very important step in AAHI's strategy to advance practical, life-saving vaccines, that can be deployed at scale where they're needed most,' said Keeley Foley, CEO of AAHI. 'Quartis' innovative cutting edge, safe, world-class CDMO capabilities makes it possible for AAHI to deliver on our mission – and helps ensure our efforts to combat infectious diseases and foster health autonomy worldwide. Together, we're not just manufacturing vaccines—we're delivering an important mission to revolutionize global health." Quratis, renowned for its global innovation in healthcare, brings unparalleled expertise in vaccine development and manufacturing to the table. With a track record of success in TB and COVID-19 vaccines like QTP101 and QTP104, Quratis' advanced processes will enhance AAHI's pipeline, ensuring high-quality, efficient production from pre-clinical stages through clinical trials. "We are honored and thrilled to join forces with AAHI, a pioneer in immune-enhancing technologies and sustainable vaccine solutions," said Soung Joon Kim, CEO of Quratis. "This partnership aligns perfectly with our vision of making people happy and healthy through borderless healthcare innovations. By supporting AAHI's pipeline, we expect to create value not only for global health, but also for our shareholders through long-term growth opportunities.' The partnership builds on existing collaborations, including the co-development of the ID93+GLA-SE tuberculosis vaccine candidate (QTP101), and underscores a shared commitment to strengthening international vaccine supply chains, advancing equitable access, and fostering worldwide manufacturing capacity for sustainable program deployment. For more information about this partnership or to explore collaboration opportunities, and order pre clinical materials please contact info@ About Access to Advanced Health Institute (AAHI) Access to Advanced Health Institute (AAHI) is a global leader in developing practical, cost-effective vaccines to combat deadly diseases such as tuberculosis, malaria, and HIV. With a mission to translate high-impact science into scalable, field-ready solutions, AAHI breaks through barriers in global health by creating innovative vaccine formulations, building worldwide manufacturing capacity, and fostering partnerships to ensure sustainable, equitable health outcomes. For more information, visit or contact us at info@ About Quratis Quratis Inc. is a leading biopharmaceutical company specializing in innovative vaccine development and advanced biologics manufacturing. With a state-of-the-art GMP facility and strong global partnerships, Quratis is at the forefront of developing next-generation vaccines against infectious diseases, including tuberculosis, COVID-19, schistosomiasis, and neglected tropical diseases. In addition to its core vaccine pipeline, Quratis offers superior CDMO capabilities, including expertise in mRNA–LNP drug delivery platforms that provide seamless bench-to-field support from research through commercial production. By combining cutting-edge R&D with scalable manufacturing, Quratis is committed to delivering high-quality, accessible, and life-saving solutions to patients worldwide. For more information, visit
Yahoo
2 hours ago
- Yahoo
Quanterix Accelerator Laboratory Awarded Rigorous New York State Clinical Laboratory Permit
Permit approval enables expanded research capabilities and underscores commitment to accuracy, reliability, and scientific excellence BILLERICA, Mass., August 21, 2025--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the New York State Department of Health (NYSDOH) has granted the Quanterix Accelerator Laboratory a clinical laboratory permit in the Clinical Chemistry category. The permit approval expands advanced biomarker research led by Quanterix, deepening collaborations with clinical, pharmaceutical, and research partners. The Quanterix Accelerator Lab is now fully CLIA-certified in all 50 states, enabling comprehensive clinical testing and biomarker analysis nationwide. "Collaboration is at the core of the Quanterix Accelerator Laboratory," said Masoud Toloue, PhD, Chief Executive Officer of Quanterix. "Every breakthrough therapy and clinical trial begins with strong partnerships. Securing this permit reaffirms our commitment to quality and compliance and enables us to extend our expertise to a broader network of clinical and research partners." The Quanterix Accelerator Laboratory is a cutting-edge facility leveraging ultra-sensitive Simoa® technology to deliver unmatched precision in protein biomarker detection, supporting biopharmaceutical research, clinical testing, and custom assay development. Certified under the Clinical Laboratory Improvement Amendments (CLIA) program, the Lab has developed 100+ custom assays and supported over 264 global clinical trials across neurology, immunology/oncology, and infectious diseases, combining rapid turnaround with dedicated project management to accelerate discovery and therapeutic innovation. The latest achievement in a series of growth milestones for the Lab, the new permit underscores Quanterix's commitment to meeting the highest benchmarks for accuracy, reliability, and safety. As one of the nation's largest healthcare markets, New York's clinical testing standards are among the most comprehensive in the country, requiring labs to meet rigorous Clinical Laboratory Evaluation Program (CLEP) standards. Accelerator's Simoa® NfL Laboratory Developed Test (LDT) gained approval as part of the laboratory permitting. Authorizations for additional clinical tests are planned to further broaden the available test menu. Additionally, operating under the Quanterix Accelerator Laboratory, the Lucent Diagnostics brand now provides advanced serum and plasma biomarker testing to the clinical and research community. This integration combines the Accelerator Lab's rigor and ultra-sensitive Simoa® technology with Lucent Diagnostics' focus on delivering actionable clinical insights, expanding the reach and impact of biomarker-driven discovery and diagnostics. To learn more about the Quanterix Accelerator Laboratory, visit: About QuanterixQuanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,600 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at View source version on Contacts Media Contact Marissa Klaassenmedia@ Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Gaxos Labs Is Surging on a New Launch. Should You Buy the AI Penny Stock Here?
Gaxos (GXAI) shares closed sharply higher on Tuesday after the artificial intelligence (AI) firm announced the official launch of a new, state-of-the-art creative engine dubbed In its press release, the startup based out of Roseland, New Jersey described Art-Gen as an AI-based image and video creation platform 'that makes pro-grade content effortless for anyone, anywhere.' More News from Barchart Should You Buy the Pullback in Palantir Stock Today? The Quantum Computing Race Is On: These 2 Stocks Appear Poised to Lead As SoFi Launches International Money Transfer Services, How Should You Play SOFI Stock? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Following today's rally, Gaxos stock is up nearly 75% versus its low set on Aug. 11. Year-to-date, however, the penny stock remains down more than 30% at writing. Why the Art-Gen Launch Is Meaningful for Gaxos Stock The Art-Gen announcement is meaningfully positive for GXAI stock because it signals a shift toward scalable, high-margin, recurring revenue. Integrating top-tier AI models with proprietary enhancements positions Gaxos at the forefront of the booming generative artificial intelligence market. The platform's ease of use, premium creative capabilities, and subscription model offer significant monetization potential, while CEO Vadim Mats' focus on commercial scalability and shareholder value reinforces investor confidence as well. All in all, with demand for AI-enabled content creation surging, Art-Gen could drive rapid user adoption, revenue growth, and long-term upside, making the launch strategically constructive for Gaxos shares. The Case Against Buying This Penny Stock at Current Levels While the launch of Art-Gen sure is bullish for GXAI, investors should remain wary of loading up on it mostly because it's a penny stock vulnerable to manipulation schemes like 'pump and dumps.' More importantly, Gaxos stock has low liquidity and limited institutional ownership, which may amplify the aforementioned risk. Another major red flag for serious investors is that GXAI shares do not currently receive coverage from Wall Street analysts as tracked by Barchart. What it means is that it's devoid of essential scrutiny, earnings forecasts, and valuation benchmarks. Without analyst coverage, investors lack independent insight into fundamentals, making it harder to assess long-term viability. The lack of Street coverage also indicates limited institutional interest and raises questions about transparency and governance as well – none of which bodes well for Gaxos stock. On the date of publication, Wajeeh Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
